argenx

argenx ARGX Stock

$925.70   -1.734530%
Add to favorites
Market Cap
$58.21B
LOW - HIGH [24H]
$925.15 - $948.67
VOLUME [24H]
$248.87K
P/E Ratio
32.06
Earnings per share
$28.87
ISIN
US04016X1019
Price   Prediction

argenx Price Chart

Sorry, that's all we've gotfor now...

argenx (ARGX) stock price today is 925.7 USD on Tech Market Large (-1.73% on the day). Updated .

argenx ARGX Financial and Trading Overview

argenx stock price 925.7 USD
Previous Close 941.25 USD
Open 939.97 USD
Bid 850.33 USD x 100
Ask 977.32 USD x 100
Day's Range 933.98 - 950.06 USD
52 Week Range 661.85 - 1072.75 USD
Volume 283.4K USD
Avg. Volume 361.17K USD
Market Cap 59.24B USD
Beta (5Y Monthly) -0.064
PE Ratio (TTM) 32.63041
EPS (TTM) 28.87 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 1150.61 USD

ARGX Valuation Measures

Enterprise Value 1.47T USD
Trailing P/E 32.63041
Forward P/E 28.278873
PEG Ratio (5 yr expected) 1.28
Price/Sales (ttm) 10.014624
Price/Book (mrq) 174.98328
Enterprise Value/Revenue 247.902
Enterprise Value/EBITDA 771.387

Trading Information

argenx Stock Price History

Beta (5Y Monthly) -0.064
52-Week Change 2.47%
S&P500 52-Week Change 12.00%
52 Week High 1072.75 USD
52 Week Low 661.85 USD
50-Day Moving Average 919.83 USD
200-Day Moving Average 861.84 USD

ARGX Share Statistics

Avg. Volume (3 month) 361.17K USD
Avg. Daily Volume (10-Days) 360.74K USD
Shares Outstanding 62.89M
Float 1.56B
Short Ratio 2.95
% Held by Insiders 0%
% Held by Institutions 45.35%
Shares Short 1.41M
Short % of Float 2.25%
Short % of Shares Outstanding 2.25%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 31.73%
Operating Margin (ttm) 31.94%
Gross Margin 59.83%
EBITDA Margin 32.13%

Management Effectiveness

Return on Assets (ttm) N/A
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) 5.92B USD
Revenue Per Share (ttm) 3.8 USD
Quarterly Revenue Growth (yoy) 52.10%
Gross Profit (ttm) 3.54B USD
EBITDA 1.9B USD
Net Income Avi to Common (ttm) 1.88B USD
Diluted EPS (ttm) 28.87
Quarterly Earnings Growth (yoy) 47.00%

Balance Sheet

Total Cash (mrq) 5.18B USD
Total Cash Per Share (mrq) 3.32 USD
Total Debt (mrq) 47M USD
Total Debt/Equity (mrq) 0.56 USD
Current Ratio (mrq) N/A
Book Value Per Share (mrq) 5.3836

Cash Flow Statement

Operating Cash Flow (ttm) N/A
Levered Free Cash Flow (ttm) N/A

Profile of argenx

Country United States
State N/A
City Amsterdam
Address Laarderhoogtweg 25
ZIP 1101 EB
Phone 31 10 703 8441
Website https://argenx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 1863

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Q&A For argenx Stock

What is a current ARGX stock price?

argenx ARGX stock price today per share is 925.7 USD.

How to purchase argenx stock?

You can buy ARGX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for argenx?

The stock symbol or ticker of argenx is ARGX.

Which industry does the argenx company belong to?

The argenx industry is Biotechnology.

How many shares does argenx have in circulation?

The max supply of argenx shares is 62.89M.

What is argenx Price to Earnings Ratio (PE Ratio)?

argenx PE Ratio is 32.06442600 now.

What was argenx earnings per share over the trailing 12 months (TTM)?

argenx EPS is 28.87 USD over the trailing 12 months.

Which sector does the argenx company belong to?

The argenx sector is Healthcare.

argenx ARGX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 22617.73 USD —
-5.28
10.6B USD — 22513.01 USD — 23837.76 USD — — 10.6B USD —
us US Tech Biotechnology NBI US 6781.89 USD —
-1.73
— — 6767.31 USD — 6980.47 USD — — — —
us US Tech Health Care IXHC US 1282.67 USD —
-1.79
— — 1279.99 USD — 1317.94 USD — — — —
us US Tech Global Select Market Com NQGS US 11139.01 USD —
-5.31
— — 11086.73 USD — 11742.47 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Next Generation 100 Inde NGX US 1607.36 USD —
-3.42
— — 1601.83 USD — 1668.4 USD — — — —
$2.04T
Total marketcap
$116.78B
Total volume
BTC 57.84%   •   ETH 9.64%
Dominance
Select currency